Article thumbnail

Potential Clinical Applications for Human Pluripotent Stem Cell-Derived Blood Components

By Erin A. Kimbrel and Shi-Jiang Lu

Abstract

The ability of human embryonic stem cells (hESCs) and induced pluripotent stem cells (iPSCs) to divide indefinitely without losing pluripotency and to theoretically differentiate into any cell type in the body makes them highly attractive cell sources for large scale regenerative medicine purposes. The current use of adult stem cell-derived products in hematologic intervention sets an important precedent and provides a guide for developing hESC/iPSC based therapies for the blood system. In this review, we highlight biological functions of mature cells of the blood, clinical conditions requiring the transfusion or stimulation of these cells, and the potential for hESC/iPSC-derivatives to serve as functional replacements. Many researchers have already been able to differentiate hESCs and/or iPSCs into specific mature blood cell types. For example, hESC-derived red blood cells and platelets are functional in tasks such as oxygen delivery and blood clotting, respectively and may be able to serve as substitutes for their donor-derived counterparts in emergencies. hESC-derived dendritic cells are functional in antigen-presentation and may be used as off-the-shelf vaccine therapies to stimulate antigen-specific immune responses against cancer cells. However, in vitro differentiation systems used to generate these cells will need further optimization before hESC/iPSC-derived blood components can be used clinically

Topics: Review Article
Publisher: SAGE-Hindawi Access to Research
OAI identifier: oai:pubmedcentral.nih.gov:3062143
Provided by: PubMed Central

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.

Suggested articles

Citations

  1. (2009). A feeder-free and efficient production of functional neutrophils from human embryonic stem cells,”
  2. (2001). a l i r i s k i ,P .L .V i e i r a ,J .H .N .S c h u i t e m a k e r
  3. (1999). A new era for cancer immunotherapy based on the genes that encode cancer antigens,”
  4. (1987). A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone,” The New England
  5. (1994). Activation of human dendritic cells through CD40 cross-linking,”
  6. (1988). Aebersold et al., “Use of tumor-infiltrating lymphocyts and interleukin-2 in the immunotherapy of patients with metastatic melanoma.
  7. (2006). andE.D.Choi,“Directeddifferentiationofhumanembryonic stem cells into functional dendritic cells through the myeloid pathway,”
  8. (2008). Aurade et al., “Megakaryocyte endomitosis is a failure of late cytokinesis related to defects in the contractile ring and Rho/Rock signaling,”
  9. (2008). Biologic properties and enucleation of red blood cells from human embryonic stem cells,”
  10. (2005). Blood Groups and Red Cell Antigens,
  11. (2002). Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes,”
  12. (2006). Cancer regression in patients after transfer of genetically engineered lymphocytes,”
  13. (2008). Cancer vaccines for established cancer: how to make them better?”
  14. (2005). D u d l e y ,J .R .W u n d e r l i c h ,J .C .Y a n ge ta l . ,“ A d o p t i v e cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma,”
  15. (2010). D.I.Godfrey,S.Stankovic,andA.G.Baxter,“RaisingtheNKT cell family,”
  16. (2006). Definitive-like erythroid cells derived from human embryonic stem cells coexpress high levels of embryonic and fetal globins with little or no adult globin,”
  17. (2000). Dendreon sets Provenge price at $93,000, says only
  18. (2006). Dendritic cells loaded with killed allogeneic melanoma cells can induce objective clinical responses and MART-1 specific CD8+ T-cell immunity,”
  19. (2007). Development and selection of γδ Tc e l l s ,
  20. (1998). Effects of cytokines on platelet production from blood and marrow CD34+ cells,”
  21. (2006). Efficient enucleation of erythroblasts differentiated in vitro from hematopoietic stem and progenitor cells,”
  22. (2002). Efficient induction of minor histocompatibility antigen HA-I-specific cytotoxic T-cellsusingdendriticcellsretrovirallytransducedwithHA-Icoding cDNA,”
  23. (2009). Engineering antigen-specific T cells from genetically modified human hematopoietic stem cells in immunodeficient mice,”
  24. (2007). Enhanced antitumor activity of T cells engineered to express T-cell receptors with a second disulfidebond,”CancerResearch,vol.67,no.8,pp.3898–3903,
  25. (2005). Ex vivo generation of fully mature human red blood cells from hematopoietic stem cells,”
  26. (2004). Generation of functional culture-derived platelets from CD34+ progenitor cells to study transgenes in the platelet environment,”
  27. (2007). Generation of functional hemangioblasts from human embryonic stem cells,”
  28. (2008). Generation of functional platelets from human embryonic stem cells in vitro via ES-sacs, VEGF-promoted structures that concentrate hematopoietic progenitors,”
  29. Generation of immunogenic dendritic cells from human embryonic stem cells without serum and feeder cells,”
  30. Generation of T cells from human embryonic stem cell-derived hematopoietic zones,”
  31. (2009). Generation of T lineage cells from human embryonic stem cells in a feeder free system,”
  32. (2009). Harnessing dendritic cells to generate cancer vaccines,”
  33. (2010). Hemangioblastic derivativesfromhumaninducedpluripotentstemcellsexhibit limited expansion and early senescence,”
  34. (2002). Hematopoietic cytokines, transcription factors and lineage commitment,”
  35. (2009). Hematopoietic development from human induced pluripotent stem cells,”
  36. (2005). Human embryonic stem cell-derived NK cells acquire functional receptors and cytolytic activity,”
  37. (2009). Human embryonic stem cells differentiate into a homogeneous population of natural killer cells with potent in vivo antitumor activity,”
  38. (2005). Human embryonic stem cells: potential tool for achieving immunotolerance?”
  39. (2004). Human marrow megakaryocyte differentiation: multiparameter correlative analysis identifies von Willebrand factor as a sensitive and distinctive marker for early (2N and 4N) megakaryocytes,”
  40. (2008). Human natural killer cells,”
  41. (2011). Human pluripotent stem cells produce natural killer cells that mediate anti-HIV1 activity by utilizing diverse cellular mechanisms,”
  42. (2009). Human-induced pluripotent stem cells from blood cells of healthy donors and patients withStem
  43. (1995). Hunt,“Plateletsgeneratedinvitrofromproplatelet-displaying human megakaryocytes are functional,”
  44. (2000). Immunotherapy of hormone-refractory prostate cancer with antigen-loaded dendritic cells,”
  45. (2003). In vitro and in vivo megakaryocyte diffe r e n t i a t i o no ff r e s ha n de xv i v o expanded cord blood cells: rapid and transient megakaryocyte reconstitution,”
  46. (2010). In vitro megakaryocyte production and platelet biogenesis: state of the art,”
  47. (2002). l b e r t s ,A .J o h n s o n ,J .L e w i s ,M .R a ff,K .R o b e r t s ,a n dP . Walter, Histology:TheLivesandDeathsofCellsinTissues(Table 22-1) in Molecular Biology of the Cell, Garland Science,
  48. (2008). L u ,C .L u o ,K .H o l t o n ,Q .F e n g ,Y .I v a n o v a ,a n dR . Lanza, “Robust generation of hemangioblastic progenitors from human embryonic stem cells,”
  49. (2006). Large-scale production of embryonic red blood cells from human embryonic stem cells,”
  50. (2006). Megakaryocytes derived from human embryonic stem cells: a genetically tractable system to study megakaryocytopoiesis and integrin function,”Journal of Thrombosis and Haemostasis,
  51. (2002). Mouse and human dendritic cell subtypes,”
  52. Nationwide blood collection and utilization survey,” Report 12-31-2007, Advancing Transfusion and Cellular Therapies Worldwide.
  53. (2009). Natural killer cell-based immunotherapy in cancer: current insights and future prospects,”
  54. (2009). Notch increases T/NK potential of human hematopoieticprogenitorsandinhibitsBcelldifferentiationat a pro-B stage,”
  55. (1985). Observations on the systemic administration of autologous lymphokineactivated killer cells and recombinant interleukin-2 to patients with metastatic cancer,” The New England
  56. (2008). Ontogeny of erythropoiesis,”
  57. (2011). Platelets generated from human embryonic stem cells are functional in vitro and in the microcirculation of living mice,” Cell Research.
  58. (2009). Prolonged continuous in vitro human platelet production using three-dimensional scaffolds,”
  59. (2004). Relationship between platelet count and bleeding risk in thrombocytopenic patients,”
  60. (2010). Risue˜ no et al., “Direct conversion of human fibroblasts to multilineage blood progenitors,”
  61. (2006). Rodr´ ıguezFern´ andez, “The multiple personalities of the chemokine receptor CCR7 in dendritic cells,”
  62. (2002). Role of CD83 in the immunomodulation of dendritic cells,”
  63. (2009). Sakata-Yanagimoto et al., “Derivation of functional mature neutrophils fromhuman embryonic stem cells,”
  64. (2003). Similarities and differences
  65. (2010). Sipuleucel-T immunotherapy for castration-resistant prostate cancer,”
  66. (2009). Smuga-Otto et al., “Hematopoietic and endothelial differentiation of human induced pluripotent stem cells,”
  67. (2006). T lineage differentiation from human embryonic stem cells,”
  68. (2001). The biology of human natural killer-cell subsets,”
  69. (2010). The challenge of immunogenicity in the quest for induced pluripotency,”
  70. (2004). The dynamic life of natural killer cells,”
  71. (2000). Transfer of specificity for human immunodeficiency virus type 1 into primary human T lymphocytes by introduction of T-cell receptor genes,”
  72. (2010). Transient activation of c-MYC expression is critical for efficient platelet generation from human induced pluripotent stem cells,”
  73. (2008). Treatment of metastatic melanoma with autologous CD4+ T cells against NY-ESO-1,” The New England
  74. (2002). u f t ,M .J e fford, P. Luetjens et al., “Functionally distinct dendritic cell (DC) populations induced by physiologic stimuli: prostaglandin E2 regulates the migratory capacity of specific
  75. (2005). V o d y a n i k ,J .A .B o r k ,J .A .T h o m s o n ,a n dI .I .S l u k v i n , “Human embryonic stem cell-derived CD34+ cells: efficient production in the coculture with OP9 stromal cells and analysis of lymphohematopoietic potential,”
  76. (1998). Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells,”
  77. (1999). Vaccination with mage-3A1peptide-pulsednature,monocyte-deriveddendritic cells expands specific cytotoxic T cells and induces regression of some metastases in advanced stage IV melanoma,”
  78. (2009). Z´ u˜ niga-Pfl¨ ucker, “Characterization in vitro and engraftment potential in vivo of human progenitor T cells generated from hematopoietic stem cells,”
  79. (2008). Z.S u,C.F ry e,K.M.Bae,V .K elley ,andJ .V ieweg,“Differentiation of human embryonic stem cells into immunostimulatory dendritic cells under feeder-free culture conditions,”